# Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19

> **NCT04368377** · PHASE2 · COMPLETED · sponsor: **University of Milan** · enrollment: 5 (actual)

## Conditions studied

- Pneumonia, Viral
- Corona Virus Infection
- Respiratory Failure
- Embolism and Thrombosis

## Interventions

- **DRUG:** Tirofiban Injection
- **DRUG:** Clopidogrel
- **DRUG:** Acetylsalicylic acid
- **DRUG:** Fondaparinux

## Key facts

- **NCT ID:** NCT04368377
- **Lead sponsor:** University of Milan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-06
- **Primary completion:** 2020-04-23
- **Final completion:** 2020-04-23
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04368377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04368377, "Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04368377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*